“It sounds like science fiction, but we’re very excited by the potential of this yeast-based vaccine production system.” — ...
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.